



Published in final edited form as:

*J Cell Immunol.* 2022 ; 4(4): 141–144. doi:10.33696/immunology.4.142.

## PD-L1 as a Novel Mediator of Lung Fibroblast to Myofibroblast Transition

Xia Guo,

Guoqing Qian\*

Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX, USA

### Keywords

Fibroblast to myofibroblast transition; Lung; PD-L1; Pulmonary fibrosis; Transforming growth factor  $\beta$

Idiopathic pulmonary fibrosis (IPF) is an incurable disease that affects approximately 3 million people worldwide [1]. Although two drugs (nintedanib and pirfenidone) have been approved for treatment of IPF, currently there is a lack of effective pharmacotherapy that could stop the progression or offer a cure for this devastating disease.

Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein that serves as a mechanism of immune surveillance. It limits excessive immune response through binding with its receptor PD-1 on T cells and suppressing their activation [2]. Increasing evidence also unveils an important role of PD-L1 in cancer cell proliferation, metastasis, and drug resistance to targeted therapy [2,3]. Recently, a few papers published support targeting PD-L1/PD-1 axis for treatment of IPF [4-7]. The treatment with an anti-PD-L1 antibody attenuates/blocks the progression of pulmonary fibrosis in preclinical models of IPF. Beyond the immune cells, new evidence has also suggested a novel role of PD-L1 in fibroblasts [5,8], particularly through a process termed fibroblast to myofibroblast transition (FMT) or myofibroblast differentiation.

Lung fibroblasts play a critical role in the progression of pulmonary fibrosis. One critical feature lies in the differentiation of fibroblasts to myofibroblasts, which express structural protein  $\alpha$ -SMA and excessive extracellular matrix, thus contributing to the structural remodeling of the lung. Myofibroblasts also entails positive feedback through secretion of profibrotic mediators, especially TGF- $\beta$ 1, the most potent inducer of profibrotic changes. Geng et al. identified a subgroup of invasive lung fibroblasts that possess high levels of PD-L1. Those fibroblasts with high PD-L1 expression can induce fibrotic changes in the

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

\*Correspondence should be addressed to Guoqing Qian, Guoqing.Qian@uthct.edu.

Conflicts of Interest

The authors have no conflict of interest to declare.

mouse lungs upon tail vein injection [6]. The finding implicates PD-L1 in the development of pulmonary fibrosis *in vivo*. Kang et al. reported that TGF- $\beta$ 1 induces PD-L1 expression using established human and murine fibroblast cell lines and PD-L1 is implicated in FMT [5]. However, the underlying mechanisms remain elusive.

The recent publication by our group [8] provides further insight on how PD-L1 mediates FMT and how it is intervened with the TGF- $\beta$  signaling. In this manuscript, the authors first demonstrated an enhanced expression of PD-L1 in the fibrotic lungs of IPF patients and mice models of pulmonary fibrosis. The finding provides a proof of concept of the implication of PD-L1 in pulmonary fibrosis. The authors further showed that TGF- $\beta$ 1 induces the expression of PD-L1 in several lines of primary lung fibroblasts from both normal and IPF donors. These data, together with a previous report using established cell lines [5], strengthen a role of PD-L1 induction by TGF- $\beta$ 1 in the FMT process. In addition, the expression of PD-L1 has also been identified in alveolar/bronchial epithelial cells [9] and alveolar macrophages [10] of IPF patients, implying various sources of PD-L1 in the pathogenesis of IPF.

Both canonical and non-canonical pathways of TGF- $\beta$ 1 signaling contribute to the FMT process and pulmonary fibrosis development. The manuscript demonstrated that PD-L1 is involved in different pathways to promote FMT. The interaction between PD-L1 and Smad3 was confirmed through immunofluorescent co-staining of PD-L1 and phosphor-Smad3 and co-immunoprecipitation (co-IP) assay. The interaction increased with the treatment of TGF- $\beta$ 1, although a basal level of interaction was also found. It remains unclear, however, whether such increased interaction (co-IP) is due to elevated expression of PD-L1 or perhaps a result of increased binding affinity. Further study is also warranted to examine the transport of PD-L1 from cytoplasm to the nucleus where co-staining of PD-L1 and phosphor-Smad3 was noted. The recent identification of the p300 as the acetyltransferase of PD-L1 provides a mechanism for the nuclear transport of PD-L1 in cancer cells [11], which deserves further investigation in the setting of lung fibroblasts, especially in view of the interactions between TGF- $\beta$  and p300 [12,13].

Whether the binding between PD-L1 with Smad3 also stabilizes phosphor-Smad3 and thereby increasing its activity needs to be addressed in future studies. Another shortcoming of the study is the overlook of Smad2 in the FMT process. Whether PD-L1 also binds with Smad2 to form a tri-complex with Smad3 deserves further investigation. Nevertheless, this manuscript presents novel findings that help explain how PD-L1 is intervened with the Smad3 signaling. This finding might be of general interest in terms of the complex role of TGF- $\beta$  in tumor progression and tissue fibrosis of other organs. Another mechanism reported in this manuscript involves the modulation of the GSK3 $\beta$ / $\beta$ -catenin signaling by PD-L1. Previous studies have reported that Wnt/ $\beta$ -catenin signaling upregulates PD-L1 transcription in diverse cancer cells [14-16]. Interestingly, PD-L1 has also been found to activate  $\beta$ -catenin signaling in different cancer cell types [14,17], suggesting potential positive feedback,  $\beta$ -catenin is a known target of GSK3 $\beta$  for ubiquitin dependent degradation. It is also implicated in lung myofibroblast differentiation [18]. The link between PD-L1 and  $\beta$ -catenin signaling provides an additional layer of control over the FMT process in the context of IPF.

The identification of the upstream regulator of PD-L1 by TGF- $\beta$  provides novel insight on the control of PD-L1 levels. Interestingly, Smad3 inhibition by a specific small molecule inhibitor SIS3 attenuates the induction of PD-L1 by TGF- $\beta$ . It seems that there exists a positive loop between Smad3 and PD-L1, i.e., Smad3 upregulates PD-L1 level which in turn binds to and increase the activity of Smad3. However, more experiments are needed to test this hypothesis. On the other hand, p38 pathway as a critical non-canonical TGF- $\beta$  signaling has also been implicated in the regulation of PD-L1. Inhibition of p38 also attenuates the induction of PD-L1 by TGF- $\beta$ . Beyond IPF, asthma related subepithelial fibrosis also benefits from the inhibition of the p38 pathway [19]. Whether targeting PD-L1 will likewise benefit fibrosis of other organs remains to be explored.

The transcriptional regulation of PD-L1 was demonstrated through an array of assays in this manuscript. It is well known that multiple mechanisms control the level of PD-L1 including manipulating its protein stability [20], e.g., the identification of March8 as a novel E3 ligase for PD-L1 degradation [21]. Whether TGF- $\beta$  signaling also affects the stability of PD-L1 remains an interesting question and warrants further experimental testing. The authors put together these findings nicely into a diagram. TGF- $\beta$  induces PD-L1 expression that is dependent on Smad3 and p38 signaling. Increased PD-L1 in turn binds to Smad3 to enhance its activation and transcriptional activity (via  $\alpha$ -SMA luciferase reporter assay). In addition, PD-L1 also contributes to upregulated  $\beta$ -catenin levels induced by TGF- $\beta$ , which is likely mediated through GSK3 $\beta$  pathway. Through those two mechanisms, PD-L1 is implicated in TGF- $\beta$  induced FMT process and potentially the development of pulmonary fibrosis. A schematic presentation of the mechanisms by which PD-L1 mediates FMT is shown in Figure 1 (Created with [BioRender.com](https://BioRender.com)).

As mentioned above, PD-L1 expression has been reported in diverse cell types including alveolar macrophages [10], alveolar epithelial cells [9,22], and lung fibroblasts [4-6,8]. Therefore, the generation of fibroblast-specific mouse model is a prerequisite for testing the role of PD-L1 in lung fibroblasts towards pulmonary fibrosis development. Currently, the conditional model is not available and future work is needed to generate the fibroblast-specific PD-L1 knockout mouse model. A recent study [23] has identified a subpopulation of alveolar type II epithelial cells (AECII) that express PD-L1 and expand in the lung of IPF patients. Due to a progenitor role of these cells, a concern is raised that PD-L1 inhibition might injure the already compromised epithelial compartment in the IPF lung. Similarly, this speculation remains to be tested using conditional PD-L1 knockout mice model.

In summary, the immune checkpoint protein PD-L1 has emerged as a novel target for the treatment of IPF. Accumulating evidence supports the targeting of PD-L1 to block the development of pulmonary fibrosis. Experiments are needed, however, to test whether inhibition of PD-L1 could reverse the already existent fibrotic lesions in the lung of IPF patients, which is often the case in the clinic. It is likely that the role of PD-L1 in the progression of pulmonary fibrosis is complex, arising from diverse cell types and involving different mechanisms. The generation of cell-specific PD-L1 knockout animal models might hold the key to unveil the full view of PD-L1 in the development of IPF.


## Acknowledgements

This work was supported by the University of Texas Health Science Center at Tyler Startup fund (to GQ and XG) and seed grant (to GQ); National Institutes of Health (R00HL141583 to XG); and the University of Texas Rising Star Award (to XG).

## References

1. Olson AL, Gifford AH, Inase N, Fernandez Perez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. *Eur Respir Rev.* 2018;27(150).
2. Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. *Sci Adv.* 2020;6(38):eabd2712. [PubMed: 32948597]
3. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *Am J Cancer Res.* 2020;10:727–42. [PubMed: 32266087]
4. Cui L, Chen SY, Lerbs T, Lee JW, Domizi P, Gordon S, et al. Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. *Nat Commun.* 2020;11:2795. [PubMed: 32493933]
5. Kang JH, Jung MY, Choudhury M, Leof EB. Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles. *FASEB J.* 2020;34:2213–26. [PubMed: 31907984]
6. Geng Y, Liu X, Liang J, Habel DM, Kulur V, Coelho AL, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. *JCI Insight.* 2019;4(6).
7. Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. *Sci Transl Med.* 2018;10(460):eaar8356. [PubMed: 30257954]
8. Guo X, Sunil C, Adeyanju o, Parker A, Huang S, Ikebe M, et al. PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and beta-catenin signaling pathways. *Sci Rep.* 2022;12:3053. [PubMed: 35197539]
9. Kronborg-White S, Madsen LB, Bendstrup E, Poletti V. PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. *J Clin Med.* 2021;10(23):5562. [PubMed: 34884264]
10. Jovanovic D, Roksandic Milenkovic M, Kotur Steviljevic J, Markovic J, Ceriman V, Kontic M, et al. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study. *J Thorac Dis.* 2018;10:6660–9. [PubMed: 30746211]
11. Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. *Nat Cell Biol.* 2020;22:1064–75. [PubMed: 32839551]
12. Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, et al. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-beta. epigenetic feed-forward amplification of fibrosis. *J Invest Dermatol.* 2013;133:1302–10. [PubMed: 23303459]
13. Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K, et al. Role of p300, a transcriptional coactivator, in signalling of TGF-beta. *Genes Cells.* 1998;3:613–23. [PubMed: 9813111]
14. Fu L, Fan J, Maity S, McFadden G, Shi Y, Kong W. PD-L1 interacts with Frizzled 6 to activate beta-catenin and form a positive feedback loop to promote cancer stem cell expansion. *Oncogene.* 2022;41:1100–13. [PubMed: 35034965]
15. Du L, Lee JH, Jiang H, Wang C, Wang S, Zheng Z, et al. beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. *J Exp Med.* 2020; 217(11):e20191115. [PubMed: 32860047]
16. Huang T, Li F, Cheng X, Wang J, Zhang W, Zhang B, et al. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. *Front Immunol.* 2021;12:619209. [PubMed: 33790893]

17. Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, et al. PD-L1 promotes tumor growth and progression by activating WIP and beta-catenin signaling pathways and predicts poor prognosis in lung cancer. *Cell Death Dis.* 2020;11:506. [PubMed: 32632098]
18. Cao H, Wang C, Chen X, Hou J, Xiang Z, Shen Y, et al. Inhibition of Wnt/beta-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. *Sci Rep.* 2018;8:13644. [PubMed: 30206265]
19. Paw M, Wnuk D, Nit K, Bobis-Wozowicz S, Szychowski R, Slusarczyk A, et al. SB203580-A Potent p38 MAPK Inhibitor Reduces the Profibrotic Bronchial Fibroblasts Transition Associated with Asthma. *Int J Mol Sci.* 2021; 22(23):12790. [PubMed: 34884593]
20. Lucibello G, Mograbi B, Milano G, Hofman P, Brest P. PD-L1 regulation revisited.impact on immunotherapeutic strategies. *Trends Mol Med.* 2021;27:868–81. [PubMed: 34187739]
21. Qian G, Guo J, Vallega KA, Hu C, Chen Z, Deng Y, et al. Membrane-associated RING-CH 8 functions as a novel PD-L1 E3 ligase to mediate PD-L1 degradation induced by EGFR inhibitors. *Mol Cancer Res.* 2021;19(10):1622–1634. [PubMed: 34183449]
22. Ahmadvand N, Khosravi F, Lingampally A, Wasnick R, Vazquez-Armendariz AI, Carraro G, et al. Identification of a novel subset of alveolar type 2 cells enriched in PD-L1 and expanded following pneumonectomy. *Eur Respir J.* 2021;58(5):2004168. [PubMed: 33863742]
23. Ahmadvand N, Carraro G, Jones MR, Shalashova I, Noori A, Wilhelm J, et al. Cell-Surface Programmed Death Ligand-1 Expression Identifies a Sub-Population of Distal Epithelial Cells Enriched in Idiopathic Pulmonary Fibrosis. *Cells.* 2022;11(10):1593. [PubMed: 35626630]



**Figure 1:**  
A diagram of the mechanisms by which PD-L1 mediates fibroblast to myofibroblast transition (FMT).